

FY 2024 Annual Performance Plan and Report
Summary of Changes in Performance Measures Table

Division	Unique Identifier	Change Type	Change	Reason for Change
NIH	SRO-5.2	Revised Target (Revised FY 2023 Target)	Launch 1-2 clinical trials testing approaches to prevent opioid and other substance misuse by intervening on social determinants of health.	The target is revised slightly to better align with current research directions.
NIH	SRO-5.18	Revised Target (Revised FY 2023 Target)	Assess the feasibility of using data mining, natural language processing (NLP), and/or other technological advances to improve health or healthcare for individuals who experience health disparities.	Target is revised to focus on a specific area of health IT research that has shown early promise in improving minority health or reducing health disparities.
NIH	SRO-5.19	Revised Target (Revised FY 2023 Target)	Receive FDA authorization or approvals for two home, point-of-care, or lab-based diagnostics, at least one of which addresses accessibility needs of people with disabilities.	Target is revised slightly to include additional information.
HRSA	3110.02	Retire	N/A	Though required by statute, the timeline for assessing and reporting this metric (every three years) is not consistent with other GPRA measures, making the assessment and target setting methodology and interpretation overly complex. Program suggests removing this measure from GPRA measure table and either incorporating the measure into a "Performance analysis" section following the performance table or including this information in the narrative section of the budget.
HRSA	3110.03	Retire	N/A	HRSA has proposes two new measures that will replace this composite measure.
HRSA	4000.03	Revise	Percentage of Ryan White HIV/AIDS Program clients who are virally suppressed.	HRSA is simplifying the wording of this measure.
HRSA	6010.01	Revise	Number of rural health research products released during the fiscal year.	HRSA is making a minor editorial change to clarify what HRSA is measuring.
CMS	MIP6	Revise FY 2021 result	1.33% (Target Met)	The MIP6 narrative description indicated the correct result of 1.33% while the results table correctly reported 1.58%. The results table was updated to report the correct result (1.33%) which now also aligns with the narrative description.
ACF	16C (MG)	Revise	Increase the percentage of refugees who are self-sufficient (not dependent on any cash assistance) within the first eight months (240 days) of the service period.	See previous.
ASPR	1.3	Revise FY 2023 and FY 2024 Targets	The out-year targets were changed prior to their fiscal years. The new targets for each year are 102,150.	The rapid advancement of the technology and methods combined with the impact of the pandemic and then transition from the pandemic necessitate recalculations to assure accuracy.
ASPR	2.4.15b	Measure Title Changed	Continue advanced research and development initiatives for more effective influenza vaccines manufactured using modern, flexible, agile technologies, and the development of influenza therapeutics for use in outpatient and hospital settings, including pediatric patients	The change reflects improved accuracy by making it more clear what is measured. Since the pandemic, BARDA's work is evolving. Biotech is advancing – they don't feel that the current measure title reflects this. BARDA wants the title to be more complete. The change adds granularity to vaccines and (most importantly) adds therapeutics for outpatient use - not just hospitalized patients. That previously wasn't needed for this measure.